BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Loftis AJ, Alabanza P, Lipansky F, Painter WP. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv 2021:2021. [PMID: 34159342 DOI: 10.1101/2021.06.17.21258639] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Berlansky S, Sallinger M, Grabmayr H, Humer C, Bernhard A, Fahrner M, Frischauf I. Calcium Signals during SARS-CoV-2 Infection: Assessing the Potential of Emerging Therapies. Cells 2022;11:253. [DOI: 10.3390/cells11020253] [Reference Citation Analysis]
2 Angel Martinez M. Efficacy of repurposed antiviral drugs: lessons from COVID-19. Drug Discovery Today 2022. [DOI: 10.1016/j.drudis.2022.02.012] [Reference Citation Analysis]
3 Tian L, Pang Z, Li M, Lou F, An X, Zhu S, Song L, Tong Y, Fan H, Fan J. Molnupiravir and Its Antiviral Activity Against COVID-19. Front Immunol 2022;13:855496. [DOI: 10.3389/fimmu.2022.855496] [Reference Citation Analysis]
4 Hashemian SMR, Pourhanifeh MH, Hamblin MR, Shahrzad MK, Mirzaei H. RdRp inhibitors and COVID-19: Is molnupiravir a good option? Biomed Pharmacother 2021;146:112517. [PMID: 34902743 DOI: 10.1016/j.biopha.2021.112517] [Reference Citation Analysis]
5 Schäfer A, Martinez DR, Won JJ, Meganck RM, Moreira FR, Brown AJ, Gully KL, Zweigart MR, Conrad WS, May SR, Dong S, Kalla R, Chun K, Du Pont V, Babusis D, Tang J, Murakami E, Subramanian R, Barrett KT, Bleier BJ, Bannister R, Feng JY, Bilello JP, Cihlar T, Mackman RL, Montgomery SA, Baric RS, Sheahan TP. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Sci Transl Med 2022;:eabm3410. [PMID: 35315683 DOI: 10.1126/scitranslmed.abm3410] [Reference Citation Analysis]
6 Shukla AK, Misra S. Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemic. J Basic Clin Physiol Pharmacol 2022. [PMID: 35503307 DOI: 10.1515/jbcpp-2022-0061] [Reference Citation Analysis]
7 Brogi S, Rossi S, Ibba R, Butini S, Calderone V, Campiani G, Gemma S. In Silico Analysis of Peptide-Based Derivatives Containing Bifunctional Warheads Engaging Prime and Non-Prime Subsites to Covalent Binding SARS-CoV-2 Main Protease (Mpro). Computation 2022;10:69. [DOI: 10.3390/computation10050069] [Reference Citation Analysis]
8 White JM, Schiffer JT, Bender Ignacio RA, Xu S, Kainov D, Ianevski A, Aittokallio T, Frieman M, Olinger GG, Polyak SJ, Prasad VR. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio 2021;12:e03347-21. [DOI: 10.1128/mbio.03347-21] [Reference Citation Analysis]
9 Saratale GD, Shin H, Shinde SK, Kim D, Saratale RG, Kadam AA, Kumar M, Bahkali AH, Syed A, Ghodake GS. Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions. JPM 2022;12:349. [DOI: 10.3390/jpm12030349] [Reference Citation Analysis]
10 Schramm R, Costard-Jäckle A, Rivinius R, Fischer B, Müller B, Boeken U, Haneya A, Provaznik Z, Knabbe C, Gummert J. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res Cardiol 2021;110:1142-9. [PMID: 34241676 DOI: 10.1007/s00392-021-01880-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Tarnawski AS, Ahluwalia A. Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs. World J Gastroenterol 2022;28:275-89. [PMID: 35110950 DOI: 10.3748/wjg.v28.i3.275] [Reference Citation Analysis]
12 Narayanan A, Toner SA, Jose J. Structure-based inhibitor design and repurposing clinical drugs to target SARS-CoV-2 proteases. Biochem Soc Trans 2022:BST20211180. [PMID: 35015073 DOI: 10.1042/BST20211180] [Reference Citation Analysis]
13 Muturi E, Hong W, Li J, Yang W, He J, Wei H, Yang H. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice. Int J Antimicrob Agents 2021;:106499. [PMID: 34929295 DOI: 10.1016/j.ijantimicag.2021.106499] [Reference Citation Analysis]
14 Law MF, Ho R, Law KWT, Cheung CKM. Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. World J Hepatol 2021; 13(12): 1850-1874 [DOI: 10.4254/wjh.v13.i12.1850] [Reference Citation Analysis]
15 Rodrigues L, Bento Cunha R, Vassilevskaia T, Viveiros M, Cunha C. Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates. Molecules 2022;27:2723. [DOI: 10.3390/molecules27092723] [Reference Citation Analysis]
16 Yin J, Li C, Ye C, Ruan Z, Liang Y, Li Y, Wu J, Luo Z. Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.01.026] [Reference Citation Analysis]
17 Li R, Liu H, Fairley CK, Zou Z, Xie L, Li X, Shen M, Li Y, Zhang L. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. Int J Infect Dis 2022:S1201-9712(22)00168-0. [PMID: 35338008 DOI: 10.1016/j.ijid.2022.03.029] [Reference Citation Analysis]
18 Tao K, Tzou PL, Nouhin J, Bonilla H, Jagannathan P, Shafer RW. SARS-CoV-2 Antiviral Therapy. Clin Microbiol Rev 2021;:e0010921. [PMID: 34319150 DOI: 10.1128/CMR.00109-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]